Definium Therapeutics, Inc. (DFTX) Stock Analysis — Probabli.AI
AI-powered analysis for DFTX (Definium Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $36.18 · Market cap: $2.7B · AI outlook: Bullish
Definium Therapeutics, Inc. (DFTX) is positioned for substantial short-term growth with promising phase 3 trial results, a significant collaboration with a pharma giant, and a strong 'strong buy' analyst consensus pointing towards potential stock appreciation. Despite facing challenges like earnings surprises and patent disputes, its innovative drug pipeline and strategic partnerships create…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 25% · Bear 20%
- 1-year price estimates — P10: $28 / P50: $55 / P90: $70
- Definium Therapeutics has shown potential for rapid short-term appreciation due to significant positive news, including promising phase 3 results and a major collaboration deal. Despite a history of missing earnings…
5-Year Outlook
- Bull 60% · Neutral 20% · Bear 20%
- 5-year price estimates — P10: $40 / P50: $95 / P90: $180
SWOT Highlights
- Strength: Promising phase 3 trial results
- Strength: Strong collaborations with major pharma companies
- Risk: Consistent earnings misses
- Risk: Negative average EPS surprise
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
15 Wall Street analysts rate DFTX a STRONG BUY with a mean price target of $48.54.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
DFTX forecast details · DFTX sentiment details · DFTX insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Definium Therapeutics, Inc. (DFTX) — saved
Definium Therapeutics, Inc. (DFTX) is positioned for substantial short-term growth with promising phase 3 trial results, a significant collaboration with a pharma giant, and a strong 'strong buy' analyst consensus pointing towards potential
- Definium Therapeutics, Inc. (DFTX) — saved
Definium Therapeutics presents significant upside potential stemming from strong drug development pipelines, FDA fast-track designation, and strategic collaborations. Analysts show high confidence in future performance with STRONG BUY conse
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.